新闻
AMPH
--
0.00%
--
第三季度需要关注的 18 种关键生物制药催化剂
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Needham analyst Serge Belanger highlighted companies in the firm's coverage universe that have key catalysts in the third...
Benzinga · 07/10 12:03
EQS-Adhoc:Cosmo Pharmaceuticals宣布董事会变更
EQS Group-Ad-hoc: Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous Cosmo Pharmaceuticals announces a change in its board of directors 10-May-2021 /...
EQS Group AG · 05/10 05:01
10-Q:AMPHASTAR PHARMACEUTICALS,INC。
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following is a discussion and...
Edgar Online - (EDG = 10Q, 10K) · 05/07 20:29
Brief-Amphastar宣布回购其Anp子公司26%的股权,并分拆其Hanxin子公司
reuters.com · 05/07 20:09
Amphastar Pharma宣布回购其ANP子公司26%的股权; ANP将分拆其中国子公司南京汉新医药科技有限公司。
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). As part of the restructuring, Amphastar will
Benzinga · 05/07 20:06
分析师提供有关医疗保健公司的见解:Amphastar Pharmaceuticals(AMPH)和Exelixis(EXEL)
SmarterAnalyst · 05/07 19:25
Amphastar Pharmaceuticals重组中国子公司以专注于药品生产;看到移动将推动21财年,22财年EPS
MT Newswires · 05/07 16:43
Amphastar Pharmaceuticals(AMPH)获得Raymond James的持有评级
Raymond James analyst Elliot Wilbur reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH) yesterday. The company's shares closed last Thursday at
SmarterAnalyst · 05/07 12:01
Amphastar Pharmaceuticals(AMPH)从Northland证券获得买入评级
Northland Securities analyst Tim Chiang reiterated a Buy rating on Amphastar Pharmaceuticals (AMPH) today and set a price target of $23.00. The company's
SmarterAnalyst · 05/07 12:01
8-K:Amphastar Pharmaceuticals,Inc.
(EDGAR Online via COMTEX) -- 0001297184false00012971842021-05-062021-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/06 22:17
简述-Amphastar Pharmaceuticals第一季度调整后的非公认会计原则每股收益$ 0.27
reuters.com · 05/06 21:58
回顾:Amphastar制药第一季度收益
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.82% over the past year to $0.27, which beat the estimate of $0.18.
Benzinga · 05/06 21:45
Amphastar Pharmaceuticals Q1每股收益$ 0.27超过$ 0.18估计,销售额$ 103.02M超过$ 97.26M估计
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.18 by 50 percent. This is a 58.82 percent increase over earnings of $0.17 per share
Benzinga · 05/06 20:51
-Earnings Flash(AMPH)AMPHASTAR PHARMACEUTICALS报告第一季度收入为1.03亿美元,而Street Est为9690万美元
MT Newswires · 05/06 16:19
简介-Amphastar Pharmaceuticals获得硫酸吗啡注射液的FDA批准
reuters.com · 05/03 12:09
Amphastar Pharmaceuticals(AMPH)将报告第一季度业绩:华尔街预计收益增长
Zacks.com · 04/29 21:06
2021年行业趋势对全球跨粘膜药物输送设备市场增长的分析:领先企业的业务洞察力,规模研究,Covid19影响的关键挑战,到2027年的商机预测
Apr 26, 2021 (The Expresswire) -- Global “Transmucosal Drug Delivery Devices Sales Market” 2021 Report provide the detailed knowledge on the forthcoming...
The Express Wire · 04/26 11:47
酮咯酸氨丁三醇市场规模2021:顶级制造商,行业份额,区域分析,类型和应用以及对2027的预测
Apr 23, 2021 (Market Stats News via COMTEX) -- The latest report as Ketorolac Tromethamine Market acknowledges Size, Application Segment, Type, Regional...
Market Stats News · 04/23 08:10
透明质酸酶动力注射剂市场规模和份额2021 |领先关键参与者的增长分析,全球有效因素,趋势,业务计划,至2027年的主要发现预测
Apr 23, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Hyaluronidase Power Injection...
The Express Wire · 04/23 05:06
2021年硬膜外麻醉药和器械市场规模:按应用和地理趋势,份额,收入,COVID-19下的行业趋势,到2027年的增长前景和预测细分的主要国家
Apr 20, 2021 (The Expresswire) -- Global “Epidural Anesthetic Drugs and Device Market" Analysis 2021-2027: Market Analysis and Insights: Global Epidural...
The Express Wire · 04/20 09:31
微牛提供丰富的实时AMPH股票新闻,让你可以通过多个平台了解AMPH股票行情最新动态,这些免费的Amphastar Pharms新闻可以帮助你做出明智投资。
AMPH 简况
Amphastar Pharmaceuticals, Inc.是一家专业制药公司。该公司主要专注于开发、制造、推广和销售仿制、注射和吸入产品。该公司通过两个部门运营:成品药部门和活性医药物成分(API)产品部门。成品药部门制造、推广及销售依诺肝素钠、Cortrosyn、Amphadase、纳洛酮、利多卡因,以及各种其他重症和非重症护理药物。API部门制造和销售重组人胰岛素和猪胰岛素。该公司生产和销售约20种产品。此外,该公司正在开发近10种仿制药简略新药申请(ANDA)、3种仿制生物和6种注射及吸入候选产品。